Medical device company Insulet Corporation (NASDAQ:PODD), a developer of tubeless insulin pump technology, has acquired assets from Bigfoot Biomedical related to its pump-based automated insulin delivery (AID) technologies, the two companies announced on Monday.

Insulet paid a total of USD25m for the acquisition, which includes certain Bigfoot patents related to pumps that may be used for AID therapy.

This transaction further strengthens Insule's intellectual property portfolio while providing Bigfoot with additional capital to expand its Bigfoot Unity Diabetes Management System to more people in need of connected insulin injection support technologies.

The agreement also includes fully paid-up licences between the parties in their respective business fields with respect to the acquired patents and other Bigfoot patents.

AID systems like Insulet's Omnipod 5 System deliver insulin through a pump that connects to and communicates with a continuous glucose monitor (CGM). Compared with AID systems, connected injection support technologies like Bigfoot Unity leverage smart pen caps to provide dose suggestions based on CGM data in connection with a healthcare professional's recommendations. Different types of insulin delivery technologies are built to address the varying needs of people with diabetes.